- In
Life Sciences
Patents
- 8 December 2020
The Australian government’s regulatory body for therapeutic goods is the Therapeutic Goods Administration (TGA). In order to lawfully supply goods classified as therapeutic goods (including biologicals, pharmaceuticals, and medical devices) in Australia, the goods must be subjected to an approval process by the TGA and listed in the Australian Register of Therapeutic Goods (ARTG). The […]
Read More
- In
Life Sciences
Patents
- 1 September 2020
In Australia, exclusive commercial rights for plant varieties can be obtained under the Plant Breeder’s Rights Act 1994 (the PBR Act). Australian plant breeder’s rights extend for 20 years for most plants, and 25 years for some vines (including kiwifruit and grapevine) and trees. The PBR Act accords with international requirements for plant variety protection […]
Read More
Science and innovation go hand in hand, as is clearly evident in the Queensland life sciences sector. Encouraging R&D in the life sciences, and protecting and promoting resulting innovation, has the potential to play a critical role in economic recovery as we move out of the COVID-19 pandemic. To that end, Life Science Queensland […]
Read More
By Tim Fitzgerald A patent confers a limited-term right to exclude other parties from using an invention, in exchange for a comprehensive description of the invention. The granted claims of a patent define the scope of the right that is conferred. Patents are jurisdiction-specific – a patent granted in one jurisdiction does not (at least […]
Read More
By Tim Fitzgerald* and Michael Finney** — ‘Swiss format’ or ‘Swiss-type’ patent claims have a general structure similar to the following: Use of compound X in the manufacture of a formulation for the treatment of medical condition Y. Swiss-type claims were originally approved by the Swiss Patent Office as a mechanism to allow for protection […]
Read More
AIPPI conference in London 14-18 September 2019 Wayne Slater will be attending the upcoming AIPPI conference in London on behalf of our firm. Wayne is a member of the AIPPI standing committee on designs and will also be taking the opportunity to meet the UK clients of the firm. This year the world Congress for […]
Read More
The annual BIO International Convention for 2019 will be held at the Pennsylvania Convention Center, Philadelphia . The delegates will gather together for unique opportunities for education and networking with some of the global leaders in biotech, pharma and life science. IP Gateway is emerging as a leading Australian firm for patent matters in the life […]
Read More
- In
Life Sciences
- 1 March 2018
OPIUM WARS By Alison McMillan PhD The Tasmanian licit opium poppy industry provides about 50% of the world’s Narcotic Raw Material (NRM). The industry is worth about $290 million to Tasmania. The Tasmanian poppy industry is controlled by three companies, SunPharma, India’s largest pharmaceutical company, Tasmanian Alkaloids Pty Ltd (Tas Alkaloids) owned by SK […]
Read More
